Business
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials –SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the second of tw
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Kura Oncology, Inc.","displaySize":"","headline":null,"caption":"Kura Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IOFGB7AyVbH8Ah1e0o_Gjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a","width":300,"height":157}},"lazy":false},{"type":"text","content":"– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials –","length":109,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the second of two KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura previously announced receipt of the first $30 million milestone triggered by patient dosing in the KOMET-017 trials in October 2025. Kura has received a total of $105 million in milestone payments to date and expects to receive up to $315 million in additional, near-term milestones under the collaboration.","length":812,"tagName":"p"},{"type":"text","content":"KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.","length":503,"tagName":"p"},{"type":"text","content":"About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to targ...